Impact News +++ ABIONYX Pharma Is Launching a Capital Increase With Cancellation of Preferential Subscription Rights in... (Business Wire) +++ ABIONYX Aktie -4,27%

CONMED Aktie

>CONMED Aktienkurs

33.4 EUR (Tradegate)

Ask: 33.6 EUR / 237 Stück

Bid: 33.2 EUR / 241 Stück

Tagesumsatz: 0 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

CONMED Aktie über LYNX handeln

Intraday

1 Jahr

>CONMED Performance

1 Woche: -0,3%

1 Monat: -7,5%

3 Monate: -24,9%

6 Monate: -27,7%

1 Jahr: -51,2%

laufendes Jahr: -50,7%

>CONMED Aktie

Name:

CONMED CORP. DL-,01

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US2074101013 / 886793

Symbol/ Ticker:

EC8 (Frankfurt) / CNMD (NYSE)

Kürzel:

FRA:EC8, ETR:EC8, EC8:GR, NYSE:CNMD

Index:

Webseite:

https://www.conmed.com/

Profil:

Conmed Corporation is a global medical technology ..
>Volltext..

Marktkapitalisierung:

1051.15 Mio. EUR

Unternehmenswert:

1745.3 Mio. EUR

Umsatz:

1145.59 Mio. EUR

EBITDA:

156.35 Mio. EUR

Nettogewinn:

54.57 Mio. EUR

Gewinn je Aktie:

1.76 EUR

Schulden:

727.2 Mio. EUR

Liquide Mittel:

33.16 Mio. EUR

Operativer Cashflow:

142.84 Mio. EUR

Bargeldquote:

0.12

Umsatzwachstum:

-0.66%

Gewinnwachstum:

-53.85%

Dividende je Aktie:

0.69 EUR

Dividendenrendite:

2.01%

Dividendenschätzung:

2.01%

Div. Historie:

15.09.25 - 0.1716€
13.06.25 - 0.1716€

>weitere anzeigen...

Insiderhandel:

1 Insider verkaufte innerhalb der letzten 30 Tage Aktien im Wert von 10.591 USD.

Suchwörter:

CONMED

Letzte Datenerhebung:

16.12.25

>CONMED Kennzahlen

Aktien/ Unternehmen:

Aktien: 30.97 Mio. St.

Frei handelbar: 96.95%

Leerverk. Aktien: 7.5%

Rückkaufquote: -

Mitarbeiter: 3900

Umsatz/Mitarb.: 0.28 Mio. EUR

Analysten:

Analystenrating: Neutral

Kursziel: 25.38%

Bewertung:

KGV: 19.6

KGV lG: 8.97

KUV: 1.05

KBV: 1.24

PEG-Ratio: -

EV/EBITDA: 11.16

Rentabilität:

Bruttomarge: 51.24%

Gewinnmarge: 4.76%

Operative Marge: 9.4%

Managementeffizenz:

Gesamtkaprendite: 2.76%

Eigenkaprendite: 6.6%

>CONMED Peer Group

Es sind 599 Aktien bekannt.

>CONMED Chart & Kurs - NYSE

>CONMED News

15.12.25 - 17:30	Here′s Why Conmed (CNMD) is a Strong Growth Stock (Zacks)
	The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage....

08.12.25 - 18:15	CONMED Stock Falls as It Strategically Exits Gastroenterology Portfolio (Zacks)
	CNMD is set to exit its gastroenterology portfolio to streamline its focus on higher-growth surgical platforms and boost long-term margins....

05.12.25 - 19:00	Why Is Conmed (CNMD) Up 0.1% Since Last Earnings Report? (Zacks)
	Conmed (CNMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues....

05.12.25 - 14:03	Olympus, Gore, and ConMed Announce Transition of Commercial Support for the GORE® VIABIL® Biliary Endoprosthesis in the United States (PR Newswire)
	CENTER VALLEY, Pa., Dec. 5, 2025 /PRNewswire/ -- Olympus Corporation ("Olympus"), W. L. Gore & Associates, Inc. ("Gore"), and ConMed Corporation ("ConMed") jointly announced today the upcoming transition of commercial support and distribution for the GORE® VIABIL® Biliary Endoprosthesis......

05.12.25 - 13:00	Zacks.com featured highlights include Plains GP, Edison International, TD SYNNEX, CONMED and PG&E (Zacks)
	Plains GP, Edison International, TD SYNNEX, CONMED and PG&E stand out for value as low EV-to-EBITDA ratios spotlight potential opportunities....

04.12.25 - 16:00	Here′s Why You Should Add CONMED Stock to Your Portfolio Now (Zacks)
	CONMED gains momentum from high-margin platforms and supply-chain recovery, even as tariffs and dV5 adoption weigh on near-term margins....

24.11.25 - 21:02	Insiderhandel: Chief Information Officer verkauft Aktien von CONMED im Wert von 10591 USD (Insiderkauf)
	Glaze, Richard - Vorstand - Tag der Transaktion: 2025-11-21...

11.11.25 - 17:31	Conmed (CNMD) is a Top-Ranked Growth Stock: Should You Buy? (Zacks)
	Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores....

10.11.25 - 17:30	Wall Street Analysts Think Conmed (CNMD) Could Surge 25.54%: Read This Before Placing a Bet (Zacks)
	The average of price targets set by Wall Street analysts indicates a potential upside of 25.5% in Conmed (CNMD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock....

08.11.25 - 01:02	Insiderhandel: Executive Vice President & CFO verkauft Aktien von CONMED im Wert von 150500 USD (Insiderkauf)
	Garner, Todd W. - Vorstand - Tag der Transaktion: 2025-11-06...

06.11.25 - 20:30	CONMED Q3 Earnings and Revenues Beat Estimates, Margins Contract (Zacks)
	CNMD beats third-quarter 2025 estimates on strength in surgery segments, but gross and operating margins see sharp contraction....

06.11.25 - 04:15	Conmed signals $150M share repurchase program and narrows 2025 revenue guidance amid strategic portfolio focus (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

06.11.25 - 03:15	Compared to Estimates, Conmed (CNMD) Q3 Earnings: A Look at Key Metrics (Zacks)
	While the top- and bottom-line numbers for Conmed (CNMD) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values....

06.11.25 - 01:45	Conmed (CNMD) Tops Q3 Earnings and Revenue Estimates (Zacks)
	Conmed (CNMD) delivered earnings and revenue surprises of +2.86% and +0.42%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?...

05.11.25 - 23:36	CONMED übertrifft Prognosen, doch die Aktie gibt nach (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

02.10.25 - 22:06

CONMED Corporation to Announce Third Quarter 2025 Financial Results on November 5, 2025 (Business Wire)

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that it will report financial results for the third quarter 2025 after the market close on Wednesday, November 5, 2025. The Company's management will host a conference call at 4:30 p.m. ET that same day to discuss the results. To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode. This conference call will also be webcast and can be accessed from the “Investors” section of CONMED's website at www.conmed.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call. About CONMED Corporation CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. For mor...

24.09.25 - 17:30	Why Conmed (CNMD) is a Top Growth Stock for the Long-Term (Zacks)
	Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores....

15.09.25 - 19:01	Insiderhandel: Aufsichtsrat verkauft Aktien von CONMED im Wert von 107049 USD (Insiderkauf)
	Farkas, Charles - Aufsichtsrat - Tag der Transaktion: 2025-09-12...

14.09.25 - 21:42	XFRA: DIVIDEND/INTEREST INFORMATION - 15.09.2025 - US2074101013 (XETRA)
	Das Instrument EC8 US2074101013 CONMED CORP. DL-,01 EQUITY wird ex Dividende/Zinsen gehandelt am 15.09.2025 The instrument EC8 US2074101013 CONMED CORP. DL-,01 EQUITY has its ex-dividend/interest day on 15.09.2025...

11.09.25 - 23:48	XFRA: DIVIDEND/INTEREST INFORMATION - 15.09.2025 - US2074101013 (XETRA)
	Das Instrument EC8 US2074101013 CONMED CORP. DL-,01 EQUITY wird cum Dividende/Zinsen gehandelt am 12.09.2025 und ex Dividende/Zinsen am 15.09.2025 The instrument EC8 US2074101013 CONMED CORP. DL-,01 EQUITY has its pre-dividend/interest day on 12.09.2025 and its ex-dividend/interest day on 15.09.2025...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Der Mensch ward zum Tun und nicht zum Vernünfteln erschaffen. Aber eben deswegen, weil er nicht dazu erschaffen ward, hängt er diesem mehr als jenem nach. - Gotthold Ephraim Lessing

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram